Journal of Vaccine Research 2024, Vol.14, No.4, 183-195 http://medscipublisher.com/index.php/jvr 190 Addressing these challenges requires a multifaceted approach, combining rigorous safety evaluations, innovative manufacturing techniques, and personalized treatment strategies to maximize the potential of adjuvants in cancer immunotherapy. 6 Innovations and Emerging Trends in Adjuvant Technology 6.1 Next-generation adjuvants The development of next-generation adjuvants is crucial for enhancing the efficacy of cancer vaccines. These adjuvants are designed to overcome the limitations of traditional adjuvants by providing stronger and more targeted immune responses. For instance, dendrimer polypeptide nanoparticles, such as KK2DP7, have shown promise in enhancing the immune efficacy of vaccines by facilitating dendritic cell migration and increasing antigen uptake and cross-presentation by antigen-presenting cells (APCs) (Zhang et al., 2023). Additionally, multifunctional protein conjugates with built-in adjuvants, which combine adjuvants and antigens into a single molecule, have demonstrated significantly higher immune responses compared to traditional adjuvants (Du et al., 2020). These innovative approaches not only improve the potency of the vaccines but also reduce systemic toxicities associated with adjuvant administration. Another promising development is the use of high-density lipoprotein-mimicking nanodiscs that co-deliver antigens and adjuvants to lymphoid organs, thereby sustaining antigen presentation on dendritic cells and eliciting robust cytotoxic T-lymphocyte responses (Kuai et al., 2017). These nanodiscs have shown up to 47-fold greater frequencies of neoantigen-specific CTLs compared to soluble vaccines, highlighting their potential in personalized cancer immunotherapy. 6.2 Personalized adjuvant strategies Personalized adjuvant strategies are emerging as a critical component of cancer vaccine development. These strategies involve tailoring adjuvants to the specific needs of individual patients based on their tumor characteristics and immune profiles. Personalized cancer vaccines (PCVs) that incorporate individualized tumor-specific antigens (neoantigens) have shown promise in modulating both the innate and adaptive immune systems to redeploy antitumor immunity. The integration of chemical strategies in PCVs provides opportunities for exploring novel adjuvants, constructing efficient delivery systems, and combining bioengineering methods to enhance vaccine potency and re-educate the tumor microenvironment (TME) (Li and Li, 2020). Moreover, the selection of adjuvants in personalized strategies must consider factors such as the patient's age, lifestyle, and concurrent treatments, as these can influence immune responses. For example, aging is associated with immunosenescence and chronic inflammation, which can impact the efficacy of cancer vaccines. Therefore, the choice of adjuvants must be carefully tailored to achieve optimal immune responses in older patients or those undergoing treatments like chemotherapy and radiotherapy (Cuzzubbo et al., 2021). 6.3 Combination adjuvants Combination adjuvants represent a promising approach to overcoming the challenges of poor antigen immunogenicity and tumor immune evasion. By targeting multiple branches of the immune response, combination adjuvants can enhance the overall efficacy of cancer vaccines. For instance, the use of combinatorial adjuvant strategies that include Toll-like receptor (TLR) agonists, STING agonists, and other immunostimulatory molecules can help stimulate robust immune responses while preventing tumor-induced immunosuppression (Bowen et al., 2018). Recent studies have demonstrated the potential of combining adjuvants to optimize dendritic cell activation and T-cell priming. The Multidimensional Synergy of Combinations (MuSyC) framework has been used to identify synergistic interactions between adjuvants, leading to optimized dosing regimens that improve antitumor responses without causing additional toxicities (Taylor et al., 2022). This approach has shown that combinations of STING agonists with TLR4 or TLR7/8 agonists can significantly enhance the activation of antigen-presenting cells and improve the efficacy of cancer vaccines in preclinical models.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==